Patient demographics and baseline clinical characteristics
| Patient characteristics . | Entire cohort N = 199 (%) . | DR cohort N = 68 (%) . | NDR cohort n = 131 (%) . | P value . |
|---|---|---|---|---|
| Groups | .029 | |||
| Proceeded to CAR T-cell infusion | 154 (77) | 46 (68) | 108 (82) | |
| Did not proceed to CAR T-cell infusion | 45 (23) | 22 (32) | 23 (18) | |
| Median age | 61 (20-83) | 60.5 (20-76) | 61 (24-83) | .16 |
| Sex | .58 | |||
| Female | 71 (36) | 22 (32) | 49 (37) | |
| Male | 128 (64) | 46 (68) | 83 (63) | |
| ECOG PS at time of intake | .25 | |||
| 0-1 | 131 (72) | 41 (64) | 90 (76) | |
| 2+ | 51 (28) | 22 (35) | 29 (24) | |
| Missing | 17 | 5 | 12 | |
| Histological subtypes | .20 | |||
| De novo DLCBL | 121 (60) | 48 (70) | 74 (56) | |
| Transformed DLBCL | 69 (35) | 17 (25) | 52 (40) | |
| PMBCL | 9 (5) | 3 (5) | 5 (4) | |
| Stage at initial diagnosis | .08 | |||
| 1-2 | 30 (21) | 8 (17) | 22 (22) | |
| 3 | 37 (25) | 8 (17) | 29 (30) | |
| 4 | 79 (54) | 32 (67) | 47 (48) | |
| Missing | 53 | 20 | 33 | |
| Disease bulk | .23 | |||
| ≤7cm | 111 (58) | 33 (52) | 78 (62) | |
| >7cm | 79 (42) | 31 (48) | 48 (38) | |
| Missing | 9 | 4 | 5 | |
| Presence of extranodal disease | ||||
| Yes | 113 (59) | 36 (56) | 77 (61) | .63 |
| No | 77 (41) | 28 (44) | 49 (39) | |
| Missing | 9 | 4 | 5 | |
| History of CNS involvement | .78 | |||
| Yes | 14 (7) | 4 (6) | 10 (8) | |
| No | 177 (93) | 60 (94) | 117 (92) | |
| Missing | 8 | 4 | 4 | |
| Relapsed and refractory status | ||||
| Primary refractory | 121 (62) | 68 (100) | 53 (44) | <.001 |
| Relapsed | 72 (38) | 0 (0) | 72 (56) | |
| Missing | 6 | 6 | ||
| Median number of lines of prior therapy for LBCL | 2 (1-3) | 2 (2-3) | 2 (1-3) | 1.00 |
| Prior ASCT | <.001 | |||
| Yes | 54 (27) | 0 (0) | 54 (41) | |
| No | 147 (73) | 68 (100) | 77 (59) | |
| Bridging therapy | ||||
| None | 57 (29) | 15 (22) | 42 (33) | .09 |
| Chemotherapy only | 43 (22) | 13 (19) | 30 (23) | |
| Radiotherapy only | 42 (21) | 20 (29) | 22 (17) | |
| Steroids only | 18 (9) | 4 (6) | 14 (11) | |
| Chemotherapy & radiotherapy | 8 (4) | 5 (7) | 3 (2) | |
| Chemotherapy & steroids | 7 (4) | 1 (1) | 6 (5) | |
| Radiotherapy & steroids | 16 (8) | 8 (12) | 8 (6) | |
| Chemotherapy, radiotherapy & steroids | 5 (3) | 2 (3) | 3 (2) | |
| Missing | 3 | 0 | 3 |
| Patient characteristics . | Entire cohort N = 199 (%) . | DR cohort N = 68 (%) . | NDR cohort n = 131 (%) . | P value . |
|---|---|---|---|---|
| Groups | .029 | |||
| Proceeded to CAR T-cell infusion | 154 (77) | 46 (68) | 108 (82) | |
| Did not proceed to CAR T-cell infusion | 45 (23) | 22 (32) | 23 (18) | |
| Median age | 61 (20-83) | 60.5 (20-76) | 61 (24-83) | .16 |
| Sex | .58 | |||
| Female | 71 (36) | 22 (32) | 49 (37) | |
| Male | 128 (64) | 46 (68) | 83 (63) | |
| ECOG PS at time of intake | .25 | |||
| 0-1 | 131 (72) | 41 (64) | 90 (76) | |
| 2+ | 51 (28) | 22 (35) | 29 (24) | |
| Missing | 17 | 5 | 12 | |
| Histological subtypes | .20 | |||
| De novo DLCBL | 121 (60) | 48 (70) | 74 (56) | |
| Transformed DLBCL | 69 (35) | 17 (25) | 52 (40) | |
| PMBCL | 9 (5) | 3 (5) | 5 (4) | |
| Stage at initial diagnosis | .08 | |||
| 1-2 | 30 (21) | 8 (17) | 22 (22) | |
| 3 | 37 (25) | 8 (17) | 29 (30) | |
| 4 | 79 (54) | 32 (67) | 47 (48) | |
| Missing | 53 | 20 | 33 | |
| Disease bulk | .23 | |||
| ≤7cm | 111 (58) | 33 (52) | 78 (62) | |
| >7cm | 79 (42) | 31 (48) | 48 (38) | |
| Missing | 9 | 4 | 5 | |
| Presence of extranodal disease | ||||
| Yes | 113 (59) | 36 (56) | 77 (61) | .63 |
| No | 77 (41) | 28 (44) | 49 (39) | |
| Missing | 9 | 4 | 5 | |
| History of CNS involvement | .78 | |||
| Yes | 14 (7) | 4 (6) | 10 (8) | |
| No | 177 (93) | 60 (94) | 117 (92) | |
| Missing | 8 | 4 | 4 | |
| Relapsed and refractory status | ||||
| Primary refractory | 121 (62) | 68 (100) | 53 (44) | <.001 |
| Relapsed | 72 (38) | 0 (0) | 72 (56) | |
| Missing | 6 | 6 | ||
| Median number of lines of prior therapy for LBCL | 2 (1-3) | 2 (2-3) | 2 (1-3) | 1.00 |
| Prior ASCT | <.001 | |||
| Yes | 54 (27) | 0 (0) | 54 (41) | |
| No | 147 (73) | 68 (100) | 77 (59) | |
| Bridging therapy | ||||
| None | 57 (29) | 15 (22) | 42 (33) | .09 |
| Chemotherapy only | 43 (22) | 13 (19) | 30 (23) | |
| Radiotherapy only | 42 (21) | 20 (29) | 22 (17) | |
| Steroids only | 18 (9) | 4 (6) | 14 (11) | |
| Chemotherapy & radiotherapy | 8 (4) | 5 (7) | 3 (2) | |
| Chemotherapy & steroids | 7 (4) | 1 (1) | 6 (5) | |
| Radiotherapy & steroids | 16 (8) | 8 (12) | 8 (6) | |
| Chemotherapy, radiotherapy & steroids | 5 (3) | 2 (3) | 3 (2) | |
| Missing | 3 | 0 | 3 |
PMBCL, primary mediastinal B-cell lymphoma.